A myeloid sentinel that secretes leukotrienes to activate type 2 immunity
分泌白三烯以激活 2 型免疫的骨髓前哨细胞
基本信息
- 批准号:10507701
- 负责人:
- 金额:$ 26.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-05 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAllergensAlveolar MacrophagesAntigensAttenuatedAutomobile DrivingBacteriaBiologyBone MarrowCD4 Positive T LymphocytesCellsChimera organismCre driverCytokine GeneDataEnzymesEpigenetic ProcessEpithelialEventFoundationsGenetic TranscriptionHelminthsImmuneImmune responseImmunityIn VitroInflammationIntestinesKnowledgeLeukotrienesLungLymphocyteLymphoid CellMaintenanceMemoryMusMyelogenousNatural ImmunityPhenotypePhysiologicalPositioning AttributeProductionPyroglyphidaeRadiation ToleranceRegulationReporterRoleSentinelSignal PathwaySignal TransductionSmall IntestinesSourceT-Cell ReceptorTestingTh2 CellsTherapeutic InterventionTimeTissuesTranscription Factor AP-1Virusadaptive immunityairway inflammationcell typecysteinyl leukotriene receptorcysteinyl-leukotrienecytokineepigenomeexperimental studyfungushelminth infectionnovelnovel therapeutic interventionreceptorresponsetranscription factortranscriptome
项目摘要
Project Summary/Abstract
Sensing is the obligate first step of any immune response, resulting in activation of early innate signals that
direct subsequent adaptive immunity. The sensing of bacteria, viruses, and fungi has been defined in detail,
but our understanding of how parasitic worms (helminths) and allergens are detected to initiate “type 2”
immunity remains lacking. Group 2 innate lymphoid cells (ILC2s) are among the first immune cells activated in
a type 2 response, but they do not directly sense foreign agonists. Instead, host-derived signals from the
surrounding tissues activate ILC2s. One such signal is cysteinyl leukotrienes (cysLT), which are required to
activate both intestinal and airway ILC2s. Over time, ILC2s are replaced by effector and memory Th2 cells that
acquire an ILC2-like transcriptional and epigenetic phenotype. These Th2 cells can be activated by IL-33 in the
absence of antigen, but a role for cysLT in driving this innate-like function has not been tested. In the intestine,
cysLTs must be produced by epithelial tuft cells, but tuft cells are largely dispensable for airway type 2
inflammation. In Aim 1 of this proposal, we seek to identify the cellular source of cysLTs that activate airway
ILC2s during helminth infection. In Aim 2, we test the cell intrinsic role of cysLT signaling in Th2 effector and
memory cells. Our studies promise to reveal tissue-specific paradigms for initiation and maintenance of type 2
immunity, thereby suggesting new strategies for therapeutic intervention.
项目总结/摘要
感觉是任何免疫反应的第一步,导致早期先天信号的激活,
直接后续适应性免疫。已经详细定义了细菌、病毒和真菌的传感,
但是我们对寄生虫(蠕虫)和过敏原如何被检测到引发“2型”的理解,
免疫力仍然缺乏。第2组先天性淋巴样细胞(ILC 2)是第一批激活的免疫细胞,
2型反应,但它们不直接感应外源激动剂。相反,来自宿主的信号
周围组织激活ILC 2。一种这样的信号是半胱氨酰白三烯(cysLT),其需要与细胞内的蛋白质结合。
激活肠道和气道ILC 2。随着时间的推移,ILC 2被效应和记忆Th 2细胞取代,
获得ILC 2样转录和表观遗传表型。这些Th 2细胞可以被IL-33激活,
不存在抗原,但cysLT在驱动这种先天样功能中的作用尚未得到测试。在肠道中,
cysLT必须由上皮丛细胞产生,但丛细胞主要是气道2型细胞
炎症在该提案的目的1中,我们试图鉴定激活气道的cysLT的细胞来源。
寄生虫感染期间的ILC 2。在目的2中,我们测试了cysLT信号传导在Th 2效应细胞中的细胞内在作用,
记忆细胞我们的研究有望揭示启动和维持2型糖尿病的组织特异性模式。
免疫,从而提出了新的治疗干预策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jakob H. von Moltke其他文献
Jakob H. von Moltke的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jakob H. von Moltke', 18)}}的其他基金
Regulation of the tuft-ILC2 circuit in the small intestine
小肠 tuft-ILC2 回路的调节
- 批准号:
10580850 - 财政年份:2022
- 资助金额:
$ 26.48万 - 项目类别:
A myeloid sentinel that secretes leukotrienes to activate type 2 immunity
分泌白三烯以激活 2 型免疫的骨髓前哨细胞
- 批准号:
10659251 - 财政年份:2022
- 资助金额:
$ 26.48万 - 项目类别:
Regulation of the tuft-ILC2 circuit in the small intestine
小肠 tuft-ILC2 回路的调节
- 批准号:
10416908 - 财政年份:2022
- 资助金额:
$ 26.48万 - 项目类别:
Tuft cell effector functions in the small intestine
簇细胞效应器在小肠中发挥作用
- 批准号:
10343684 - 财政年份:2020
- 资助金额:
$ 26.48万 - 项目类别:
Tuft cell effector functions in the small intestine
簇细胞效应器在小肠中发挥作用
- 批准号:
10555217 - 财政年份:2020
- 资助金额:
$ 26.48万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 26.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 26.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 26.48万 - 项目类别: